Quotes 5-day view Delayed Nasdaq
02/22/2021
02/23/2021
02/24/2021
02/25/2021
02/26/2021
Date
157.58(c)
157.03(c)
155.02(c)
150.09(c)
151.11(c)
Last
865 379
1 218 028
1 199 818
1 022 564
1 698 964
Volume
-0.11%
-0.35%
-1.28%
-3.18%
+0.68%
Change
Sales 2021
1 504 M
-
-
Net income 2021
-393 M
-
-
Net cash position 2021
2 025 M
-
-
P/E ratio 2021
-69,9x
Yield 2021
-
Sales 2022
2 273 M
-
-
Net income 2022
89,2 M
-
-
Net cash position 2022
2 456 M
-
-
P/E ratio 2022
351x
Yield 2022
-
Capitalization
27 376 M
27 376 M
-
EV / Sales 2021
16,9x
EV / Sales 2022
11,0x
Nbr of Employees
2 092
Free-Float
99,4%
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV...
Notations Surperformance© of Seagen Inc.
Trading Rating :
Investor Rating :
All news about SEAGEN INC.
News in other languages on SEAGEN INC.
Analyst Recommendations on SEAGEN INC.
Wall Street closes broadly higher on deal news, vaccine hopes
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SEAGEN INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
19
Average target price
190,76 $
Last Close Price
151,11 $
Spread / Highest target
68,1%
Spread / Average Target
26,2%
Spread / Lowest Target
-8,68%
Please enable JavaScript in your browser's settings to use dynamic charts.